Literature DB >> 19515643

The science of pterygia.

J C Bradley1, W Yang, R H Bradley, T W Reid, I R Schwab.   

Abstract

Pterygium is an ocular surface disease of humans attributed to chronic ultraviolet-B exposure. Clinically, the condition involves invasive centripetal growth with associated inflammation and neovascularisation. Previous clinical studies focused primarily on the clinical characteristics and surgical management of pterygia and, because of this, the pathogenesis of pterygia remains incompletely understood. However, considerable progress in this area has been achieved, providing additional insight into this complex disease. This recent evidence implicates antiapoptotic mechanisms, immunological mechanisms, cytokines, growth factors, extracellular matrix modulators, genetic factors, viral infections and other possible causative factors. Limited investigation regarding differences in pathogenesis of primary and recurrent pterygia has been performed. We summarise many of these recent discoveries concerning the pathogenesis of pterygia and describe reported differences between primary and recurrent pterygia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515643     DOI: 10.1136/bjo.2008.151852

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  60 in total

1.  Relations between lymphangiogenesis and the size of pterygium.

Authors:  Lin Liu; Shi-Qi Ling; Qiao-Li Li; Tao Wang; Hui Ye; Jie-Zhen Yang; Xiu-Hua Jia
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

2.  Topical dobesilate eye drops for ophthalmic primary pterygium.

Authors:  Pedro Cuevas; Luis A Outeiriño; Javier Angulo; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-03-08

3.  Survivin and p53 expression in primary and recurrent pterygium in Chinese patients.

Authors:  Li-Wei Zhang; Bai-Hua Chen; Xing-Hua Xi; Qian-Qian Han; Luo-Sheng Tang
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

4.  The study of etiological and demographic characteristics of pterygium recurrence: a consecutive case series study from Pakistan.

Authors:  P Salim Mahar; Nabeel Manzar
Journal:  Int Ophthalmol       Date:  2013-06-18       Impact factor: 2.031

5.  Effect of porcine chondrocyte-derived extracellular matrix on the pterygium in mouse model.

Authors:  Hye Sook Lee; Ji Hyun Lee; Jae Wook Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-23       Impact factor: 3.117

6.  EphB4 expression in pterygium is associated with microvessel density.

Authors:  Chunyan Xue; Yueqin Chen; Zhenping Huang; Yirui Ge; Haiyan Wang; Jiandong Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

7.  Identification of pterygium-related mRNA expression profiling by microarray analysis.

Authors:  J Liu; X Ding; L Yuan; X Zhang
Journal:  Eye (Lond)       Date:  2017-06-30       Impact factor: 3.775

8.  Expression of prostaglandin E2 receptor subtypes in human pterygium and normal conjunctiva: immunohistochemical study.

Authors:  Erdem Dinç; Özer Dursun; Banu Yılmaz; Mustafa Vatansever; A Ayça Sarı; Özlem Yıldırım; Ufuk Adıgüzel
Journal:  Int Ophthalmol       Date:  2017-07-10       Impact factor: 2.031

9.  Risk factors for pterygium recurrence after limbal-conjunctival autografting: a retrospective, single-centre investigation.

Authors:  Naser Samadi Aidenloo; Qader Motarjemizadeh; Maryam Heidarpanah
Journal:  Jpn J Ophthalmol       Date:  2018-03-16       Impact factor: 2.447

10.  miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium.

Authors:  David H Engelsvold; Tor P Utheim; Ole K Olstad; Pedro Gonzalez; Jon R Eidet; Torstein Lyberg; Anne-Marie S Trøseid; Darlene A Dartt; Sten Raeder
Journal:  Exp Eye Res       Date:  2013-07-19       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.